BiotechTube
Home/Nuvation Bio/David Hanley, Ph.D.
DH

David Hanley, Ph.D.

Chief Technical Operations Officer

Nuvation Bio

Therapeutic Areas

Oncology

Nuvation Bio Pipeline

DrugIndicationPhase
NUV-868Advanced Solid TumorsPhase 1/2
NUV-1511Advanced Solid TumorsPhase 1
TalazoparibHRR-deficient Cancers (e.g., Breast)Approved
PidilizumabHematologic Cancers (e.g., DLBCL)Phase 3-ready

Leadership Team at Nuvation Bio

DH
David Hung, M.D.
Founder, President and Chief Executive Officer
View full Nuvation Bio profile